Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KRRO Stock Forecast 2026-2027
$12.05
Current Price
$173.79M
Market Cap
Buy 7
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to KRRO Price Targets
+149.0%
To High Target of $30.00
+82.6%
To Median Target of $22.00
-33.6%
To Low Target of $8.00
KRRO Price Momentum
-7.5%
1 Week Change
-5.0%
1 Month Change
-22.6%
1 Year Change
+50.4%
Year-to-Date Change
-78.4%
From 52W High of $55.89
+131.6%
From 52W Low of $5.20
📊 TOP ANALYST CALLS
Did KRRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Korro Bio is one of their latest high-conviction picks.
Latest KRRO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, KRRO has a bullish consensus with a median price target of $22.00 (ranging from $8.00 to $30.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $12.05, the median forecast implies a 82.6% upside. This outlook is supported by 7 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 149.0% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 33.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRRO Analyst Ratings
7
Buy
2
Hold
0
Sell
KRRO Price Target Range
Low
$8.00
Average
$22.00
High
$30.00
Current: $12.05
Latest KRRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | Raymond James | Steven Seedhouse | Outperform | Upgrade | $23.00 |
| Mar 13, 2026 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Maintains | $22.00 |
| Feb 19, 2026 | Clear Street | Bill Maughan | Buy | Upgrade | $18.00 |
| Feb 17, 2026 | William Blair | Myles Minter | Outperform | Upgrade | $N/A |
| Jan 29, 2026 | Piper Sandler | Yasmeen Rahimi | Overweight | Upgrade | $30.00 |
| Jan 29, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Upgrade | $20.00 |
| Jan 29, 2026 | Chardan Capital | Keay Nakae | Buy | Upgrade | $15.00 |
| Jan 28, 2026 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Upgrade | $21.00 |
| Jan 28, 2026 | Oppenheimer | Kostas Biliouris | Outperform | Upgrade | $22.00 |
| Nov 14, 2025 | Jones Trading | Catherine Novack | Hold | Downgrade | $N/A |
| Nov 13, 2025 | Cantor Fitzgerald | Steve Seedhouse | Neutral | Downgrade | $N/A |
| Nov 13, 2025 | Chardan Capital | Keay Nakae | Neutral | Downgrade | $7.00 |
| Nov 13, 2025 | William Blair | Myles Minter | Market Perform | Downgrade | $N/A |
| Nov 13, 2025 | RBC Capital | Luca Issi | Sector Perform | Downgrade | $8.00 |
| Nov 13, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Neutral | Downgrade | $N/A |
| Oct 31, 2025 | Clear Street | Bill Maughan | Buy | Initiates | $93.00 |
| Aug 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $25.00 |
| Aug 13, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $147.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $90.00 |
| Jul 24, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
Korro Bio, Inc. (KRRO) Competitors
The following stocks are similar to Korro Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Korro Bio, Inc. (KRRO) Financial Data
Valuation Metrics
Market Cap
$173.79M
Enterprise Value
$160.73M
P/E Ratio
N/A
PEG Ratio
-1.7x
Price/Sales
29.1x
Growth & Margins
Revenue Growth (YoY)
-43.1%
Gross Margin
N/A
Operating Margin
-1,229.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+43.2%
Current Ratio
6.9x
Debt/Equity
84.5x
ROE
-110.7%
ROA
-32.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Korro Bio, Inc. (KRRO) Business Model
About Korro Bio, Inc.
What They Do
Develops RNA editing genetic medicines for diseases.
Business Model
Korro Bio Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of genetic medicines that harness RNA editing technology. The company generates revenue by advancing its proprietary therapies through clinical trials and eventually commercializing them for treating various diseases, particularly those related to genetic disorders.
Additional Information
The company's lead program, KRRO-110, targets Alpha-1 Antitrypsin Deficiency and is currently in Phase 1/2 clinical trials. Korro Bio Inc. is also working on additional therapies for hyperammonemia and has collaborations to explore treatments for cardiometabolic diseases and neurodegenerative disorders. Its innovative OPERA platform allows for precise RNA edits, positioning it as a competitive player in the genetic medicine space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
58
CEO
Dr. Ram Aiyar MBA, Ph.D.
Country
United States
IPO Year
2019
Website
www.korrobio.comKorro Bio, Inc. (KRRO) Latest News & Analysis
Latest News
Quick Summary
Korro Bio announced plans for a regulatory filing of KRRO-121 for hyperammonemia in late 2026 and highlighted other R&D programs. An $85M private placement will extend cash runway to late 2028.
Why It Matters
Korro Bio's advancements in RNA editing and upcoming regulatory filings position it for significant growth, while the successful funding bolsters its financial stability through 2028.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro, Bio, Inc. (Nasdaq: KRRO) will participate in the HCW 4th Annual BioConnect Nasdaq Investor Conference, featuring key executives in a fireside chat format.
Why It Matters
Korro's participation in investor conferences highlights its efforts to attract investor interest and communicate advancements in its RNA editing technology, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), indicating positive sentiment regarding its earnings prospects, which may boost the stock price soon.
Why It Matters
Korro Bio's Zacks Rank upgrade to #2 indicates increased confidence in its earnings potential, likely boosting investor interest and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Korro, Inc. (Nasdaq: KRRO) will present data on its RNA editing technology (OPERA®) at upcoming scientific conferences, focusing on genetic medicines for rare and prevalent diseases.
Why It Matters
Korro's presentations on its RNA editing technology could signal advancements in genetic medicine, potentially boosting investor confidence and stock value in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) announced a non-statutory stock option grant to a new employee, focusing on RNA editing for rare diseases.
Why It Matters
Korro Bio's stock option grant signals growth and recruitment, which may enhance innovation and future performance, impacting investor confidence and potential stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) nominated a development candidate for hyperammonemia treatment and plans another by Q2 2026. An $85M private placement extends cash runway to late 2028.
Why It Matters
Korro Bio's development candidates for rare diseases and their extended cash runway signal potential for growth and innovation, which could enhance stock valuation and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KRRO Stock
What is Korro Bio, Inc.'s (KRRO) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Korro Bio, Inc. (KRRO) has a median price target of $22.00. The highest price target is $30.00 and the lowest is $8.00.
Is KRRO stock a good investment in 2026?
According to current analyst ratings, KRRO has 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KRRO stock?
Wall Street analysts predict KRRO stock could reach $22.00 in the next 12 months. This represents a 82.6% increase from the current price of $12.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Korro Bio, Inc.'s business model?
Korro Bio Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of genetic medicines that harness RNA editing technology. The company generates revenue by advancing its proprietary therapies through clinical trials and eventually commercializing them for treating various diseases, particularly those related to genetic disorders.
What is the highest forecasted price for KRRO Korro Bio, Inc.?
The highest price target for KRRO is $30.00 from Yasmeen Rahimi at Piper Sandler, which represents a 149.0% increase from the current price of $12.05.
What is the lowest forecasted price for KRRO Korro Bio, Inc.?
The lowest price target for KRRO is $8.00 from Luca Issi at RBC Capital, which represents a -33.6% decrease from the current price of $12.05.
What is the overall KRRO consensus from analysts for Korro Bio, Inc.?
The overall analyst consensus for KRRO is bullish. Out of 13 Wall Street analysts, 7 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are KRRO stock price projections?
Stock price projections, including those for Korro Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:08 AM UTC